{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:45:10Z","timestamp":1789728310697,"version":"4.0.1"},"publisher-location":"Cham","reference-count":130,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031598142","type":"print"},{"value":"9783031598159","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-59815-9_22","type":"book-chapter","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:01:55Z","timestamp":1723154515000},"page":"307-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19 Pneumonia and Cytokine Storm Syndrome"],"prefix":"10.1007","author":[{"given":"Frank Leo","family":"van de Veerdonk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"22_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nri1732","volume":"5","author":"S Perlman","year":"2005","unstructured":"Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5:917\u201327.","journal-title":"Nat Rev Immunol"},{"key":"22_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/jmv.20255","volume":"75","author":"KJ Huang","year":"2005","unstructured":"Huang KJ, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75:185\u201394.","journal-title":"J Med Virol"},{"key":"22_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529\u201339.","journal-title":"Semin Immunopathol"},{"key":"22_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782\u201393.","journal-title":"JAMA"},{"key":"22_CR5","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"W. H. O. R. E. A. f. C.-T. W. Group","year":"2020","unstructured":"W. H. O. R. E. A. f. C.-T. W. Group, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330\u201341.","journal-title":"JAMA"},{"key":"22_CR6","first-page":"2281","volume":"327","author":"R Rubin","year":"2022","unstructured":"Rubin R. Baricitinib is first approved COVID-19 immunomodulatory treatment. JAMA. 2022;327:2281.","journal-title":"JAMA"},{"key":"22_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","volume":"326","author":"W. H. O. R. E. A. f. C.-T. W. Group","year":"2021","unstructured":"W. H. O. R. E. A. f. C.-T. W. Group, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499\u2013518.","journal-title":"JAMA"},{"key":"22_CR8","doi-asserted-by":"publisher","first-page":"e1010367","DOI":"10.1371\/journal.pgen.1010367","volume":"18","author":"G Butler-Laporte","year":"2022","unstructured":"Butler-Laporte G, et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. PLoS Genet. 2022;18:e1010367.","journal-title":"PLoS Genet"},{"key":"22_CR9","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI van der Made","year":"2020","unstructured":"van der Made CI, et al. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020;324:663\u201373.","journal-title":"JAMA"},{"key":"22_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41577-020-0343-0","volume":"20","author":"LA Teuwen","year":"2020","unstructured":"Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389\u201391.","journal-title":"Nat Rev Immunol"},{"key":"22_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417\u20138.","journal-title":"Lancet"},{"key":"22_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41577-022-00762-9","volume":"22","author":"EM Conway","year":"2022","unstructured":"Conway EM, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22:639\u201349.","journal-title":"Nat Rev Immunol"},{"key":"22_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","volume":"74","author":"P Bastard","year":"2022","unstructured":"Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL. Type I interferons and SARS-CoV-2: from cells to organisms. Curr Opin Immunol. 2022;74:172\u201382.","journal-title":"Curr Opin Immunol"},{"key":"22_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang EY, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283\u20138.","journal-title":"Nature"},{"key":"22_CR15","doi-asserted-by":"publisher","first-page":"7450739","DOI":"10.1155\/2022\/7450739","volume":"2022","author":"I Koc","year":"2022","unstructured":"Koc I, Unalli Ozmen S. Eosinophil levels, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in the cytokine storm period of patients with COVID-19. Int J Clin Pract. 2022;2022:7450739.","journal-title":"Int J Clin Pract"},{"key":"22_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"22_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934\u201343.","journal-title":"JAMA Intern Med"},{"key":"22_CR18","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41590-020-0762-x","volume":"21","author":"JY Zhang","year":"2020","unstructured":"Zhang JY, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21:1107\u201318.","journal-title":"Nat Immunol"},{"key":"22_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"},{"key":"22_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.bjid.2020.07.010","volume":"24","author":"MP Vizcaychipi","year":"2020","unstructured":"Vizcaychipi MP, et al. Increase in COVID-19 inpatient survival following detection of Thromboembolic and Cytokine storm risk from the point of admission to hospital by a near real time Traffic-light System (TraCe-Tic). Braz J Infect Dis. 2020;24:412\u201321.","journal-title":"Braz J Infect Dis"},{"key":"22_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/pathogens10060692","volume":"10","author":"K Eljaaly","year":"2021","unstructured":"Eljaaly K, et al. Description and analysis of cytokine storm in registered COVID-19 clinical trials: a systematic review. Pathogens. 2021;10:692.","journal-title":"Pathogens"},{"key":"22_CR22","doi-asserted-by":"publisher","first-page":"e0253894","DOI":"10.1371\/journal.pone.0253894","volume":"16","author":"AKG Melo","year":"2021","unstructured":"Melo AKG, et al. Biomarkers of cytokine storm as red flags for severe and fatal COVID-19 cases: a living systematic review and meta-analysis. PLoS One. 2021;16:e0253894.","journal-title":"PLoS One"},{"key":"22_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/art.41285","volume":"72","author":"LA Henderson","year":"2020","unstructured":"Henderson LA, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059\u201363.","journal-title":"Arthritis Rheumatol"},{"key":"22_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/BOR.0000000000000822","volume":"33","author":"P Mehta","year":"2021","unstructured":"Mehta P, Fajgenbaum DC. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol. 2021;33:419\u201330.","journal-title":"Curr Opin Rheumatol"},{"key":"22_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/15353702211068840","volume":"247","author":"JM Liu","year":"2022","unstructured":"Liu JM, Chi J. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis? Exp Biol Med (Maywood). 2022;247:330\u20137.","journal-title":"Exp Biol Med (Maywood)"},{"key":"22_CR26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1473-3099(22)00348-6","volume":"22","author":"C Spaner","year":"2022","unstructured":"Spaner C, Goubran M, Setiadi A, Chen LYC. COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes. Lancet Infect Dis. 2022;22:937\u20138.","journal-title":"Lancet Infect Dis"},{"key":"22_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3949\/ccjm.87a.ccc008","volume":"87","author":"LH Calabrese","year":"2020","unstructured":"Calabrese LH. Cytokine storm and the prospects for immunotherapy with COVID-19. Cleve Clin J Med. 2020;87:389\u201393.","journal-title":"Cleve Clin J Med"},{"key":"22_CR28","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3389\/fimmu.2020.02132","volume":"11","author":"V Castelli","year":"2020","unstructured":"Castelli V, Cimini A, Ferri C. Cytokine storm in COVID-19: \u201cwhen you come out of the storm, you won\u2019t be the same person who walked in\u201d. Front Immunol. 2020;11:2132.","journal-title":"Front Immunol"},{"key":"22_CR29","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/S2665-9913(21)00011-4","volume":"3","author":"RQ Cron","year":"2021","unstructured":"Cron RQ. COVID-19 cytokine storm: targeting the appropriate cytokine. Lancet Rheumatol. 2021;3:e236\u20137.","journal-title":"Lancet Rheumatol"},{"key":"22_CR30","doi-asserted-by":"publisher","first-page":"e13429","DOI":"10.1111\/eci.13429","volume":"51","author":"R Mulchandani","year":"2021","unstructured":"Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Investig. 2021;51:e13429.","journal-title":"Eur J Clin Investig"},{"key":"22_CR31","doi-asserted-by":"publisher","first-page":"558898","DOI":"10.3389\/fimmu.2020.558898","volume":"11","author":"R de la Rica","year":"2020","unstructured":"de la Rica R, Borges M, Gonzalez-Freire M. COVID-19: in the eye of the cytokine storm. Front Immunol. 2020;11:558898.","journal-title":"Front Immunol"},{"key":"22_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3390\/idr13020036","volume":"13","author":"ML Ciampa","year":"2021","unstructured":"Ciampa ML, et al. Absence of \u201ccytokine storm\u201d in hospitalized COVID-19 patients: a retrospective cohort study. Infect Dis Rep. 2021;13:377\u201387.","journal-title":"Infect Dis Rep"},{"key":"22_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/acr2.11220","volume":"3","author":"B Ayesha","year":"2021","unstructured":"Ayesha B, et al. Rapid implementation of a multidisciplinary COVID-19 cytokine storm syndrome task force. ACR Open Rheumatol. 2021;3:133\u20137.","journal-title":"ACR Open Rheumatol"},{"key":"22_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/jcm10020297","volume":"10","author":"S Cappanera","year":"2021","unstructured":"Cappanera S, et al. When does the cytokine storm begin in COVID-19 patients? A quick score to recognize it. J Clin Med. 2021;10:297.","journal-title":"J Clin Med"},{"key":"22_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s13054-020-03267-w","volume":"24","author":"G Riva","year":"2020","unstructured":"Riva G, et al. COVID-19: more than a cytokine storm. Crit Care. 2020;24:549.","journal-title":"Crit Care"},{"key":"22_CR36","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","volume":"180","author":"P Sinha","year":"2020","unstructured":"Sinha P, Matthay MA, Calfee CS. Is a \u201ccytokine storm\u201d relevant to COVID-19? JAMA Intern Med. 2020;180:1152\u20134.","journal-title":"JAMA Intern Med"},{"key":"22_CR37","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2665-9913(20)30343-X","volume":"2","author":"BJ Webb","year":"2020","unstructured":"Webb BJ, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020;2:e754\u201363.","journal-title":"Lancet Rheumatol"},{"key":"22_CR38","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.2147\/JIR.S320685","volume":"14","author":"C Herr","year":"2021","unstructured":"Herr C, et al. Distinct patterns of blood cytokines beyond a cytokine storm predict mortality in COVID-19. J Inflamm Res. 2021;14:4651\u201367.","journal-title":"J Inflamm Res"},{"key":"22_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/medicina58020144","volume":"58","author":"C Zanza","year":"2022","unstructured":"Zanza C, et al. Cytokine storm in COVID-19: immunopathogenesis and therapy. Medicina (Kaunas). 2022;58:144.","journal-title":"Medicina (Kaunas)"},{"key":"22_CR40","doi-asserted-by":"publisher","first-page":"8879","DOI":"10.3390\/ijms23168879","volume":"23","author":"O Kalinina","year":"2022","unstructured":"Kalinina O, et al. Cytokine storm signature in patients with moderate and severe COVID-19. Int J Mol Sci. 2022;23:8879.","journal-title":"Int J Mol Sci"},{"key":"22_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","volume":"108","author":"J Wang","year":"2020","unstructured":"Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108:17\u201341.","journal-title":"J Leukoc Biol"},{"key":"22_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12989","volume":"93","author":"XH Luo","year":"2021","unstructured":"Luo XH, Zhu Y, Mao J, Du RC. T cell immunobiology and cytokine storm of COVID-19. Scand J Immunol. 2021;93:e12989.","journal-title":"Scand J Immunol"},{"key":"22_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/JLB.5CE0920-613R","volume":"109","author":"BD Pence","year":"2021","unstructured":"Pence BD. Atypical monocytes in COVID-19: lighting the fire of cytokine storm? J Leukoc Biol. 2021;109:7\u20138.","journal-title":"J Leukoc Biol"},{"key":"22_CR44","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/jmv.27405","volume":"94","author":"M Manik","year":"2022","unstructured":"Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol. 2022;94:869\u201377.","journal-title":"J Med Virol"},{"key":"22_CR45","doi-asserted-by":"publisher","first-page":"155365","DOI":"10.1016\/j.cyto.2020.155365","volume":"138","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. An inter-correlated cytokine network identified at the center of cytokine storm predicted COVID-19 prognosis. Cytokine. 2021;138:155365.","journal-title":"Cytokine"},{"key":"22_CR46","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","volume":"26","author":"DM Del Valle","year":"2020","unstructured":"Del Valle DM, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636\u201343.","journal-title":"Nat Med"},{"key":"22_CR47","doi-asserted-by":"publisher","first-page":"eabe3024","DOI":"10.1126\/sciadv.abe3024","volume":"6","author":"PA Mudd","year":"2020","unstructured":"Mudd PA, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. Sci Adv. 2020;6:eabe3024.","journal-title":"Sci Adv"},{"key":"22_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","volume":"146","author":"T Herold","year":"2020","unstructured":"Herold T, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146:128\u2013136.e124.","journal-title":"J Allergy Clin Immunol"},{"key":"22_CR49","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"Q Ruan","year":"2020","unstructured":"Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846\u20138.","journal-title":"Intensive Care Med"},{"key":"22_CR50","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S2213-2600(20)30404-5","volume":"8","author":"DE Leisman","year":"2020","unstructured":"Leisman DE, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233\u201344.","journal-title":"Lancet Respir Med"},{"key":"22_CR51","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s12024-021-00414-9","volume":"18","author":"P Frisoni","year":"2022","unstructured":"Frisoni P, et al. Cytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1beta, IL-6, IL-15 and TNF-alpha. Forensic Sci Med Pathol. 2022;18:4\u201319.","journal-title":"Forensic Sci Med Pathol"},{"key":"22_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12985-021-01588-y","volume":"18","author":"J Wang","year":"2021","unstructured":"Wang J, et al. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction. Virol J. 2021;18:117.","journal-title":"Virol J"},{"key":"22_CR53","first-page":"101292","volume":"31","author":"AF Ribeiro Dos Santos Miggiolaro","year":"2020","unstructured":"Ribeiro Dos Santos Miggiolaro AF, et al. Covid-19 cytokine storm in pulmonary tissue: anatomopathological and immunohistochemical findings. Respir Med Case Rep. 2020;31:101292.","journal-title":"Respir Med Case Rep"},{"key":"22_CR54","doi-asserted-by":"publisher","first-page":"18277","DOI":"10.1038\/s41598-020-75260-w","volume":"10","author":"G Lorenz","year":"2020","unstructured":"Lorenz G, et al. Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients. Sci Rep. 2020;10:18277.","journal-title":"Sci Rep"},{"key":"22_CR55","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"key":"22_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1535370220962043","volume":"246","author":"NN Hakim","year":"2021","unstructured":"Hakim NN, Chi J, Olazagasti C, Liu JM. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients. Exp Biol Med (Maywood). 2021;246:5\u20139.","journal-title":"Exp Biol Med (Maywood)"},{"key":"22_CR57","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1111\/bjh.16934","volume":"190","author":"H Wood","year":"2020","unstructured":"Wood H, et al. Secondary HLH is uncommon in severe COVID-19. Br J Haematol. 2020;190:e283\u20135.","journal-title":"Br J Haematol"},{"key":"22_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.chom.2020.05.007","volume":"28","author":"G Dimopoulos","year":"2020","unstructured":"Dimopoulos G, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28:117\u2013123.e111.","journal-title":"Cell Host Microbe"},{"key":"22_CR59","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1002\/jmv.27068","volume":"93","author":"B Gursoy","year":"2021","unstructured":"Gursoy B, et al. Cytokine storm in severe COVID-19 pneumonia. J Med Virol. 2021;93:5474\u201380.","journal-title":"J Med Virol"},{"key":"22_CR60","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/art.41763","volume":"73","author":"C Kessel","year":"2021","unstructured":"Kessel C, et al. Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers. Arthritis Rheumatol. 2021;73:1791\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"22_CR61","first-page":"505","volume":"22","author":"S Brikman","year":"2020","unstructured":"Brikman S, Bieber A, Dori G. The hyper-inflammatory response in adults with severe COVID-19 pneumonia differs from the cytokine storm of hemophagocytic syndrome. Isr Med Assoc J. 2020;22:505\u201313.","journal-title":"Isr Med Assoc J"},{"key":"22_CR62","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s13204-021-02115-9","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, He ZX, Wang FK. Evaluation of ferritin level in COVID-19 patients and its inflammatory response. Appl Nanosci. 2022;13:3121.","journal-title":"Appl Nanosci"},{"key":"22_CR63","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00277-021-04735-1","volume":"101","author":"G Dong","year":"2022","unstructured":"Dong G, et al. Hemophagocytosis, hyper-inflammatory responses, and multiple organ damages in COVID-19-associated hyperferritinemia. Ann Hematol. 2022;101:513\u201320.","journal-title":"Ann Hematol"},{"key":"22_CR64","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00277-022-04813-y","volume":"101","author":"M Lucijanic","year":"2022","unstructured":"Lucijanic M, et al. Higher ferritin levels in COVID-19 patients are associated with hyperinflammation, worse prognosis, and more bacterial infections without pronounced features of hemophagocytosis. Ann Hematol. 2022;101:1119\u201321.","journal-title":"Ann Hematol"},{"key":"22_CR65","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1016\/S2665-9913(20)30335-0","volume":"2","author":"RQ Cron","year":"2020","unstructured":"Cron RQ, Schulert GS, Tattersall RS. Defining the scourge of COVID-19 hyperinflammatory syndrome. Lancet Rheumatol. 2020;2:e727\u20139.","journal-title":"Lancet Rheumatol"},{"key":"22_CR66","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/MOP.0000000000001061","volume":"33","author":"GS Schulert","year":"2021","unstructured":"Schulert GS, Blum SA, Cron RQ. Host genetics of pediatric SARS-CoV-2 COVID-19 and multisystem inflammatory syndrome in children. Curr Opin Pediatr. 2021;33:549\u201355.","journal-title":"Curr Opin Pediatr"},{"key":"22_CR67","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/v14081699","volume":"14","author":"AC Zanchettin","year":"2022","unstructured":"Zanchettin AC, et al. Role of genetic polymorphism present in macrophage activation syndrome pathway in post mortem biopsies of patients with COVID-19. Viruses. 2022;14:1699.","journal-title":"Viruses"},{"key":"22_CR68","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41431-021-00886-x","volume":"29","author":"H Luo","year":"2021","unstructured":"Luo H, et al. Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. Eur J Hum Genet. 2021;29:1312\u20135.","journal-title":"Eur J Hum Genet"},{"key":"22_CR69","first-page":"417","volume":"11","author":"A Vagrecha","year":"2022","unstructured":"Vagrecha A, et al. Hemophagocytic lymphohistiocytosis gene variants in multisystem inflammatory syndrome in children. Biology (Basel). 2022;11:417.","journal-title":"Biology (Basel)"},{"key":"22_CR70","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/infdis\/jiv550","volume":"213","author":"GS Schulert","year":"2016","unstructured":"Schulert GS, et al. Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis. 2016;213:1180\u20138.","journal-title":"J Infect Dis"},{"key":"22_CR71","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes BJ, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217:e20200652.","journal-title":"J Exp Med"},{"key":"22_CR72","first-page":"e138999","volume":"5","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:e138999.","journal-title":"JCI Insight"},{"key":"22_CR73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-021-00665-1","volume":"22","author":"B Afzali","year":"2022","unstructured":"Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22:77\u201384.","journal-title":"Nat Rev Immunol"},{"key":"22_CR74","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1182\/blood.2020007008","volume":"136","author":"EA Middleton","year":"2020","unstructured":"Middleton EA, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169\u201379.","journal-title":"Blood"},{"key":"22_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41577-021-00558-3","volume":"22","author":"NK Bjorkstrom","year":"2022","unstructured":"Bjorkstrom NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol. 2022;22:112\u201323.","journal-title":"Nat Rev Immunol"},{"key":"22_CR76","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41423-020-00557-9","volume":"18","author":"S Varchetta","year":"2021","unstructured":"Varchetta S, et al. Unique immunological profile in patients with COVID-19. Cell Mol Immunol. 2021;18:604\u201312.","journal-title":"Cell Mol Immunol"},{"key":"22_CR77","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","volume":"600","author":"M Witkowski","year":"2021","unstructured":"Witkowski M, et al. Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature. 2021;600:295\u2013301.","journal-title":"Nature"},{"key":"22_CR78","doi-asserted-by":"publisher","first-page":"eabd6832","DOI":"10.1126\/sciimmunol.abd6832","volume":"5","author":"C Maucourant","year":"2020","unstructured":"Maucourant C, et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020;5:eabd6832.","journal-title":"Sci Immunol"},{"key":"22_CR79","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.immuni.2021.09.002","volume":"54","author":"B Kramer","year":"2021","unstructured":"Kramer B, et al. Early IFN-alpha signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity. 2021;54:2650\u20132669.e2614.","journal-title":"Immunity"},{"key":"22_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720109","volume":"12","author":"R Knoll","year":"2021","unstructured":"Knoll R, Schultze JL, Schulte-Schrepping J. Monocytes and macrophages in COVID-19. Front Immunol. 2021;12:720109.","journal-title":"Front Immunol"},{"key":"22_CR81","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1186\/s13054-020-03166-0","volume":"24","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk FL, Netea MG. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit Care. 2020;24:445.","journal-title":"Crit Care"},{"key":"22_CR82","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41467-020-17834-w","volume":"11","author":"C Guo","year":"2020","unstructured":"Guo C, et al. Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun. 2020;11:3924.","journal-title":"Nat Commun"},{"key":"22_CR83","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41422-020-00455-9","volume":"31","author":"E Wauters","year":"2021","unstructured":"Wauters E, et al. Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res. 2021;31:272\u201390.","journal-title":"Cell Res"},{"key":"22_CR84","doi-asserted-by":"publisher","first-page":"e329","DOI":"10.1016\/S2665-9913(22)00064-9","volume":"4","author":"J Pfeifer","year":"2022","unstructured":"Pfeifer J, et al. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. Lancet Rheumatol. 2022;4:e329\u201337.","journal-title":"Lancet Rheumatol"},{"key":"22_CR85","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cytogfr.2021.01.004","volume":"58","author":"G Opdenakker","year":"2021","unstructured":"Opdenakker G, Van Damme J. Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity. Cytokine Growth Factor Rev. 2021;58:134\u201340.","journal-title":"Cytokine Growth Factor Rev"},{"key":"22_CR86","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2665-9913(20)30165-X","volume":"2","author":"RQ Cron","year":"2020","unstructured":"Cron RQ. Coronavirus is the trigger but the immune response is deadly. Lancet Rheumatol. 2020;2:e370\u20131.","journal-title":"Lancet Rheumatol"},{"key":"22_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41591-021-01643-9","volume":"28","author":"FL van de Veerdonk","year":"2022","unstructured":"van de Veerdonk FL, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28:39\u201350.","journal-title":"Nat Med"},{"key":"22_CR88","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S2665-9913(21)00353-2","volume":"4","author":"DA Kelmenson","year":"2022","unstructured":"Kelmenson DA, Cron RQ. Who, what, and when-effective therapy for severe COVID-19. Lancet Rheumatol. 2022;4:e2\u20133.","journal-title":"Lancet Rheumatol"},{"key":"22_CR89","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","volume":"397","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397:2253\u201363.","journal-title":"Lancet"},{"key":"22_CR90","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","volume":"385","author":"A Investigators","year":"2021","unstructured":"Investigators A, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385:790\u2013802.","journal-title":"N Engl J Med"},{"key":"22_CR91","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","volume":"385","author":"R-C Investigators","year":"2021","unstructured":"Investigators R-C, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385:777\u201389.","journal-title":"N Engl J Med"},{"key":"22_CR92","doi-asserted-by":"publisher","first-page":"e57555","DOI":"10.7554\/eLife.57555","volume":"9","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk FL, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. elife. 2020;9:e57555.","journal-title":"elife"},{"key":"22_CR93","doi-asserted-by":"publisher","first-page":"e2017708","DOI":"10.1001\/jamanetworkopen.2020.17708","volume":"3","author":"FL van de Veerdonk","year":"2020","unstructured":"van de Veerdonk FL, et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020;3:e2017708.","journal-title":"JAMA Netw Open"},{"key":"22_CR94","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","volume":"9","author":"J Aman","year":"2021","unstructured":"Aman J, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021;9:957\u201368.","journal-title":"Lancet Respir Med"},{"key":"22_CR95","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/infdis\/jiaa646","volume":"223","author":"AH de Nooijer","year":"2021","unstructured":"de Nooijer AH, et al. Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J Infect Dis. 2021;223:214\u201324.","journal-title":"J Infect Dis"},{"key":"22_CR96","doi-asserted-by":"publisher","first-page":"100995","DOI":"10.1016\/j.blre.2022.100995","volume":"57","author":"EHT Lim","year":"2022","unstructured":"Lim EHT, et al. Complement activation in COVID-19 and targeted therapeutic options: a scoping review. Blood Rev. 2022;57:100995.","journal-title":"Blood Rev"},{"key":"22_CR97","doi-asserted-by":"publisher","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","volume":"2","author":"APJ Vlaar","year":"2020","unstructured":"Vlaar APJ, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;2:e764\u201373.","journal-title":"Lancet Rheumatol"},{"key":"22_CR98","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar APJ, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10:1137\u201346.","journal-title":"Lancet Respir Med"},{"key":"22_CR99","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"R. C. Group","year":"2021","unstructured":"R. C. Group, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704.","journal-title":"N Engl J Med"},{"key":"22_CR100","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2020.17021","volume":"324","author":"BM Tomazini","year":"2020","unstructured":"Tomazini BM, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307\u201316.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"22_CR101","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1916","volume":"8","author":"T Kishimoto","year":"2006","unstructured":"Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8(Suppl 2):S2.","journal-title":"Arthritis Res Ther"},{"key":"22_CR102","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095\u2013147.","journal-title":"Blood"},{"key":"22_CR103","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333\u201344.","journal-title":"N Engl J Med"},{"key":"22_CR104","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/jamainternmed.2021.2209","volume":"181","author":"X Mariette","year":"2021","unstructured":"Mariette X, et al. Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial. JAMA Intern Med. 2021;181:1241\u20133.","journal-title":"JAMA Intern Med"},{"key":"22_CR105","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","volume":"181","author":"O Hermine","year":"2021","unstructured":"Hermine O, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32\u201340.","journal-title":"JAMA Intern Med"},{"key":"22_CR106","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20\u201330.","journal-title":"N Engl J Med"},{"key":"22_CR107","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503\u201316.","journal-title":"N Engl J Med"},{"key":"22_CR108","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"R. C. Group","year":"2021","unstructured":"R. C. Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637\u201345.","journal-title":"Lancet"},{"key":"22_CR109","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"R-C Investigators","year":"2021","unstructured":"Investigators R-C, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491\u2013502.","journal-title":"N Engl J Med"},{"key":"22_CR110","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jama.2021.9508","volume":"326","author":"R Caricchio","year":"2021","unstructured":"Caricchio R, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA. 2021;326:230\u20139.","journal-title":"JAMA"},{"key":"22_CR111","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","volume":"9","author":"C.-C. group","year":"2021","unstructured":"C.-C. group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;9:295\u2013304.","journal-title":"Lancet Respir Med"},{"key":"22_CR112","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","volume":"27","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27:1752\u201360.","journal-title":"Nat Med"},{"key":"22_CR113","doi-asserted-by":"publisher","first-page":"e66125","DOI":"10.7554\/eLife.66125","volume":"10","author":"E Kyriazopoulou","year":"2021","unstructured":"Kyriazopoulou E, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. elife. 2021;10:e66125.","journal-title":"elife"},{"key":"22_CR114","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S2213-2600(21)00539-7","volume":"10","author":"HL Leavis","year":"2022","unstructured":"Leavis HL, van de Veerdonk FL, Murthy S. Stimulating severe COVID-19: the potential role of GM-CSF antagonism. Lancet Respir Med. 2022;10:223\u20134.","journal-title":"Lancet Respir Med"},{"key":"22_CR115","doi-asserted-by":"publisher","first-page":"eabg9873","DOI":"10.1126\/sciimmunol.abg9873","volume":"6","author":"RS Thwaites","year":"2021","unstructured":"Thwaites RS, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021;6:eabg9873.","journal-title":"Sci Immunol"},{"key":"22_CR116","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","volume":"10","author":"Z Temesgen","year":"2022","unstructured":"Temesgen Z, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:237\u201346.","journal-title":"Lancet Respir Med"},{"key":"22_CR117","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","volume":"10","author":"BA Fisher","year":"2022","unstructured":"Fisher BA, et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir Med. 2022;10:255\u201366.","journal-title":"Lancet Respir Med"},{"key":"22_CR118","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1164\/rccm.202108-1859OC","volume":"205","author":"GJ Criner","year":"2022","unstructured":"Criner GJ, et al. Anti-granulocyte-macrophage colony-stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2022;205:1290\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"22_CR119","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2665-9913(21)00070-9","volume":"3","author":"PC Cremer","year":"2021","unstructured":"Cremer PC, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3:e410\u20138.","journal-title":"Lancet Rheumatol"},{"key":"22_CR120","doi-asserted-by":"publisher","first-page":"2101870","DOI":"10.1183\/13993003.01870-2021","volume":"61","author":"J Patel","year":"2023","unstructured":"Patel J, et al. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). Eur Respir J. 2023;61:2101870.","journal-title":"Eur Respir J"},{"key":"22_CR121","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1016\/S2665-9913(21)00078-3","volume":"3","author":"P Mehta","year":"2021","unstructured":"Mehta P, Chambers RC, Dagna L. Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe? Lancet Rheumatol. 2021;3:e394\u20135.","journal-title":"Lancet Rheumatol"},{"key":"22_CR122","doi-asserted-by":"publisher","first-page":"107961","DOI":"10.1016\/j.intimp.2021.107961","volume":"99","author":"A Fakharian","year":"2021","unstructured":"Fakharian A, et al. Evaluation of adalimumab effects in managing severe cases of COVID-19: a randomized controlled trial. Int Immunopharmacol. 2021;99:107961.","journal-title":"Int Immunopharmacol"},{"key":"22_CR123","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17:353\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"22_CR124","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med"},{"key":"22_CR125","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407\u201318.","journal-title":"Lancet Respir Med"},{"key":"22_CR126","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"Ely EW, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327\u201336.","journal-title":"Lancet Respir Med"},{"key":"22_CR127","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(22)00088-1","volume":"10","author":"CR Wolfe","year":"2022","unstructured":"Wolfe CR, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10:888\u201399.","journal-title":"Lancet Respir Med"},{"key":"22_CR128","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","volume":"385","author":"PO Guimaraes","year":"2021","unstructured":"Guimaraes PO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385:406\u201315.","journal-title":"N Engl J Med"},{"key":"22_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13898","volume":"53","author":"A Ferrarini","year":"2023","unstructured":"Ferrarini A, et al. Early administration of tofacitinib in COVID-19 pneumonitis: an open randomised controlled trial. Eur J Clin Investig. 2023;53:e13898.","journal-title":"Eur J Clin Investig"},{"key":"22_CR130","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/S2665-9913(22)00044-3","volume":"4","author":"MK Han","year":"2022","unstructured":"Han MK, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol. 2022;4:e351\u201361.","journal-title":"Lancet Rheumatol"}],"container-title":["Advances in Experimental Medicine and Biology","Cytokine Storm Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-59815-9_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T22:05:25Z","timestamp":1723154725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-59815-9_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031598142","9783031598159"],"references-count":130,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-59815-9_22","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"9 August 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}